STAT3 and melanoma: Whether TLR4 signaling activates STAT3 through the MYD88 and TRIF pathways in the two cancer types, as we observed in melanoma, and whether TLR4/STAT3 signaling plays a pathogenic role in the two cancers warrant further investigations.